Tibalosin is a phenylethylamine derivative patented by Continental Pharma as a potent vasodilator. Tibalosine interacts specifically with alpha- and beta-adrenergic receptors and calcium channel binding sites. In preclinical models, Tibalosin exerts favor influences on arterial pressure in the hypertensive animal. The drug has acceptable toxicity in experimental animals and has been well tolerated by normal human subjects in daily doses of up to 200 mg.

Milacemide, a prodrug for glycine, is an inhibitor of the B form of monoamine oxidase. This drug could enhance dopaminergic activity in the brain and could be used as therapy for Parkinson's disease. Milacemide participated in clinical trials as a treatment for senile dementia of the Alzheimer type (SDAT). However, results have shown the drug was not an effective treatment in enhancing cognition in SDAT patients. In addition, milacemide has been tested for antiepileptic efficacy; however, this study was discontinued.

Thiocarlide (or tiocarlide or isoxyl) is a drug which was used in the treatment of tuberculosis. In addition was preclinical experiments, which showed, that it purely bacteriostatic against M. leprae. The precise mechanism is still unknown but was shown, that Delta9-desaturase could be a target for it. The more recent experiments have revealed, that Thiocarlide inhibits the dehydration step by the (3R)-hydroxyacyl dehydratases HadAB and HadBC.

Suloctidil is considered to be calcium antagonist. In addition to its vascular antispasmodic activity, suloctidil affects blood platelets and enhances brain energy metabolism. Suloctidil was being evaluated in many clinical trials for use in dementia and thrombotic disorders. Suloctidil induces hepatotoxicity.

Clopirac is a non-steroidal anti-inflammatory drug. It is a weak inhibitor of prostaglandin synthetase and has standard anti-inflammatory and analgesic activity. It effectivity inhibits prostaglandin synthesis in vitro. The metabolites of clopirac in humans and monkeys include the glucuronide of clopirac and the pyrrole carboxylic acid. Efficacy of clopirac in rheumatoid arthritis, trauma conditions, osteoarthritis and pain was evaluated in many clinical trials.

Milacemide, a prodrug for glycine, is an inhibitor of the B form of monoamine oxidase. This drug could enhance dopaminergic activity in the brain and could be used as therapy for Parkinson's disease. Milacemide participated in clinical trials as a treatment for senile dementia of the Alzheimer type (SDAT). However, results have shown the drug was not an effective treatment in enhancing cognition in SDAT patients. In addition, milacemide has been tested for antiepileptic efficacy; however, this study was discontinued.

Suloctidil is considered to be calcium antagonist. In addition to its vascular antispasmodic activity, suloctidil affects blood platelets and enhances brain energy metabolism. Suloctidil was being evaluated in many clinical trials for use in dementia and thrombotic disorders. Suloctidil induces hepatotoxicity.